期刊文献+

孟鲁司特联合布地奈德气雾剂治疗咳嗽变异型哮喘疗效观察 被引量:7

下载PDF
导出
摘要 目的观察孟鲁司特联合布地奈德气雾剂治疗咳嗽变异型哮喘的疗效。方法将60例咳嗽变异型哮喘患者随机分成2组:治疗组30例予孟鲁司特10 mg每晚睡前口服,布地奈德气雾剂(普米克)200μg早晚各1吸;对照组30例仅予布地奈德气雾剂200μg早晚各1吸。每组均按需吸入沙丁胺醇气雾剂。观察治疗前后临床疗效、肺功能变化及症状评分、PEF昼夜变异率。结果治疗后2组临床症状、PEF昼夜变异率均明显改善,治疗组症状、PEF昼夜变异率较对照组改善更明显。结论孟鲁司特联合布地奈德气雾剂治疗咳嗽变异型哮喘,可明显改善临床症状及PEF昼夜变异率。
出处 《现代中西医结合杂志》 CAS 2009年第34期4216-4218,共3页 Modern Journal of Integrated Traditional Chinese and Western Medicine
  • 相关文献

参考文献11

  • 1Lee SY,Cho JY, Shim J, et al. Airway inflammation as an assess-ment of chronic nonproductive cough [ J ]. Chest, 2001,120 ( 4 ) : 1114 - 1120.
  • 2钟南山,赖克方.咳嗽的诊断与治疗指南(草案)[J].诊断学理论与实践,2006,5(2):187-192. 被引量:35
  • 3陈树宝,主编.儿科学新理论新技术[M].上海:上海科技教育出版社,1997:115-116.
  • 4刘莹.顺尔宁[J].中国新药杂志,2001,10(2):136-137. 被引量:71
  • 5Pizzichinie EJA, left TF, Reiss L, et al. Montelukast reduces air way eosinophilic inflammation in asthma: a randomized controlied trial[J ]. Eur Respir J, 1999,12 : 1184 - 1190.
  • 6Hans B, Kim G, Nielsen. Broncho protection with a leukotrienes recept or antagonist in asthmatic preschol children[J ]. Am J Respis Crit Med,2000,162:187 - 190.
  • 7陈再历.哮喘药物的应用技术[J].中国实用儿科杂志,2001,16(12):760-762. 被引量:105
  • 8武玉清,张洪泉.白三烯受体拮抗剂孟鲁司特的研究进展[J].国外医学(药学分册),2003,30(5):284-287. 被引量:72
  • 9Peters-Golden M,Henderson WR Jr. Leukotrienes[J]. N Engl J Med,2007,357(18) :1841 - 1854.
  • 10Stankova J,Tureotte S, Harris J, et al. Modulation of leukotriene 134 receptor- 1 expression by dexamethasone: potential mechanism for enhanced neutrophil survival[ J ]. Immunol, 2002,168 : 3570 - 3576.

二级参考文献30

  • 1Soren pedersen.药物装置:为合适病人选择合适的装置[J].哮喘杂志,1999,5(3):163-163.
  • 2Steinshamn S, Sandsund M, Sue-Chu M, et al. Effects of montelukast on physical performance and exercise economy in adult asthmatics with exercise-induced bronchoconstriction[J]. Scand J Med Sci Sports , 2002, 12(4):211-217.
  • 3Niewoehner DE. Montelukast improved pulmonary function and asthma-specific quality of life in aspirin-intolerant asthma[J]. ACP J Club, 2002, 137(1):20.
  • 4Zhang J, Yu C, Noonan G, et al. Effect of montelukast, a once-daily leukotriene receptor antagonist, on peak expiratory flow variability[J]. Clin Ther, 2002, 24(4):574-582.
  • 5Stelmach I, Jerzynska J, Kuna P. A randomized, double-blind trial of the effect of treatment with montelukast on bronchial hyperresportsiveness and serum eosinophilic cationic protein (ECP), soluble interleukin 2 receptor ( sIL-2R), IL-4, and soluble intercellular adhesion molecule 1(sICAM-1) in children with asthma[J]. J Allergy Clin Immunol, 2002, 109(2) :257 - 263.
  • 6Dempsey O J, Kennedy G, Lipworth BJ. Comparative efficacy and anti-inflammatory profile of once-daily therapy with leukolriene antagonist or low-dose inhaled corticosteroid in patients with mild persistent asthma [ J ]. J Allergy Clin Immunol, 2002, 109(1):68-74.
  • 7Phipatanakul W, Nowak-Wegrzyn A, Eggleston PA, et al.The efficacy of montelukast in the treatment of cat allergen-induced asthma in children[J]. J Allergy Clin Immunol,2002, 109(5) :794 - 799.
  • 8Henderson WR Jr, Tang LO, Chu SJ, at al. A role for cysteinyl leukotrienes in airway remodeling in a mouse asthma model[J]. Am J Respir Crit Care Med, 2002, 165(1):108- 116.
  • 9Fregonese L, Silvestri M, Sabatini F, et al. Cysteinyl leukotrienes induce human eosinophil locomotion and adhesion molecule expression via a CysLT1 receptor-mediated mechanism[J]. Clin Exp Allergy, 2002, 32(5):745 -750.
  • 10Minoguchi K, Kohno Y, Minoguchi H, et al. Reduction of eosinophilic inflammation in the airways of patients with asthma using montelukast[J]. Chest, 2002, 121 (3):732 - 738.

共引文献277

同被引文献58

引证文献7

二级引证文献51

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部